Holen Sie sich die Stockscreener-App
30.07
0.96%
-0.29
Handel nachbörslich:
30.20
0.13
+0.43%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
Day Trade: Is TG Therapeutics Inc still a buy after recent gains2026 Review & Stepwise Trade Execution Plans - baoquankhu1.vn
CapEx per share of TG Therapeutics, Inc. – MIL:1TGTX - TradingView
(TGTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
TG Therapeutics (TGTX) reports financial results for Q4 and full year 2025 - MSN
TG Therapeutics, Inc. (TGTX) Enters $750 Million Term Loan Agreement – SEC 8-K Filing Summary - Minichart
Form 8K TG Therapeutics Inc For: 20 March By Investing.com - Investing.com Canada
TG Therapeutics Files Procedural 8-K on Financial Obligation - TipRanks
Form 8K TG Therapeutics Inc For: 20 March - Investing.com
TG Therapeutics (TGTX) secures $750M 2026 Term Loan maturing 2031 - Stock Titan
TG Therapeutics (TGTX) Secures $750 Million Credit Facility - GuruFocus
TG Therapeutics secures $750M credit facility with Blue Owl By Investing.com - Investing.com India
TG Therapeutics board expands share repurchase program to $300M - TipRanks
TG Therapeutics secures $750M credit facility with Blue Owl - Investing.com
TG Therapeutics (TGTX) Secures $750M Credit Facility, Expands Sh - GuruFocus
TG Therapeutics Receives $500 Million in New Capital From Blue Owl, Increases Share Buyback - marketscreener.com
TG Therapeutics secures an additional $500 million in non-dilutive capital from Blue Owl and expands share repurchase program to $300 million - marketscreener.com
TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million - TradingView
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million - ChartMill
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 earnings call transcript - MSN
Penn Capital Management Company LLC Grows Stock Position in TG Therapeutics, Inc. $TGTX - MarketBeat
Is the options market predicting a spike in TG Therapeutics stock? - MSN
TG Therapeutics Analysis: Strong Clinical Data Boost Briumvi Prospects - timothysykes.com
TG Therapeutics (NASDAQ:TGTX) Shares Up 7.9%Here's What Happened - MarketBeat
TGTX Stock Price, Quote & Chart | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
How BRIUMVI’s Strong High‑Risk MS Data At TG Therapeutics (TGTX) Has Changed Its Investment Story - simplywall.st
TGTX SEC FilingsTg Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
TGTX Q4 earnings lag estimates, Briumvi sales drive top line - MSN
TG Therapeutics to present BRIUMVI data at neurology meeting - Investing.com Nigeria
A Look At TG Therapeutics (TGTX) Valuation After New BRIUMVI Efficacy Data In Relapsing Multiple Sclerosis - simplywall.st
TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup - ChartMill
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(TGTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Briumvi momentum leads to strong execution for TG Therapeutics (TGTX) - MSN
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) - Yahoo Finance
WINTON GROUP Ltd Buys 113,951 Shares of TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? - Yahoo Finance
TGTX: Positive Phase 3 Analysis Results for Briumvi in Treating Multiple Sclerosis - GuruFocus
MS patients on BRIUMVI saw far fewer relapses and brain lesions - Stock Titan
Bank of America Securities bearish on TG Therapeutics (TGTX) post earnings - MSN
Data Published in Neurology and Therapy Demonstrate - GlobeNewswire
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio - Yahoo Finance
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story - Yahoo Finance
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI‑Led Earnings And Autoimmune Pipeline Updates - Yahoo Finance
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings - Finviz
TGTX (TG Therapeutics) Total Assets : $1,063.3 Mil (As of Dec. 2025) - GuruFocus
Is TG Therapeutics Inc. (NKB2) stock included in top ETFs2026 Buyback Activity & AI Forecast Swing Trade Picks - Naître et grandir
TG Therapeutics to present BRIUMVI data at neurology meeting By Investing.com - Investing.com Canada
TG Therapeutics (TGTX) sees price target drop from JPMorgan - MSN
TG Therapeutics, Inc. $TGTX Stake Cut by Teachers Retirement System of The State of Kentucky - MarketBeat
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - Bitget
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - The Manila Times
TG Therapeutics Azer Cel Milestone Adds Depth To Autoimmune Valuation Story - Sahm
Reports Suggest TG Therapeutics May Be Scaling Back Operations Amid Speculation on CafePharma Forum - geneonline.com
TG Therapeutics Q2 EPS Estimate Lowered by HC Wainwright - MarketBeat
TG Therapeutics Q4 EPS Forecast Lowered by HC Wainwright - MarketBeat
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):